KALV Stock Analysis: Buy, Sell, or Hold?
KALV - KalVista Pharmaceuticals, Inc. Common Stock
$19.90
0.13 (0.66%)
▲
5d:
+5.01%
30d:
+21.56%
90d:
+23.22%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Mar 24, 2026
0d
Smart Money Distribution
KALV is up 6.6% this week, but smart money is buying puts. Top strike: $15 2026-04-17 with 5,000 OI. Put ratio: 100% View Scanner →
Strength: 8.3/10
Get Alerted When KALV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: KALV is 9.9% above fair value ($18.10). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: KALV is 9.9% above fair value ($18.10). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: KALV is currently trading at $19.90, which is considered extended relative to its 30-day fair value range of $15.69 to $18.10.
Technical Outlook: Technically, KALV is in a uptrend. Immediate support is located at $15.95, while resistance sits at $21.30.
Market Sentiment: KALV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.00 (+70.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KALV is in a uptrend. Immediate support is located at $15.95, while resistance sits at $21.30.
Market Sentiment: KALV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.00 (+70.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$15.69 -
$18.10
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range (+9.9% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 70.9% below Wall St target ($34.00)
Fair Price Analysis
30-Day Fair Range
$15.69 -
$18.10
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$15.95
Resistance Level
$21.31
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.13
Wall Street Target
$34.00
(+70.9%)
Revenue Growth (YoY)
30.7%
Share & Embed Analysis
Last updated: April 02, 2026 7:03 PM ET
Data refreshes hourly during market hours. Next update: 8:03 PM
Data refreshes hourly during market hours. Next update: 8:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KALV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin L Palleiko
SELL
6693 shares
2026-03-09
Benjamin L Palleiko
SELL
10034 shares
2026-02-23
Brian Piekos
SELL
1767 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 53 HOLD |
